Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.
Location: Spain
Employees: 11-50
Total raised: $123.99M
Founded date: 2009
Funding Rounds 4
| Date | Series | Amount | Investors |
| 30.03.2026 | - | $67M | Centre for... |
| 15.07.2025 | - | $14.5M | European I... |
| 27.01.2025 | - | $26.3M | - |
| 18.04.2022 | - | $16.2M | - |
Mentions in press and media 15
| Date | Title | Description |
| 30.03.2026 | Oncomatryx: $67 Million Raised To Advance Quantum ADC Cancer Therapies | Oncomatryx has raised $67 million to support the clinical development of its next-generation antibody-drug conjugates, known as Quantum ADCs, targeting the tumor microenvironment in metastatic solid tumors. The financing round was backed by... |
| 16.07.2025 | Europe's Oncology Pioneer Secures €12.5M Funding for ADC Breakthroughs | Oncomatryx Biopharma, a leading biotechnology firm, has secured a pivotal €12.5 million EIC Accelerator funding. This significant investment, a €2.5 million grant plus €10 million equity, underscores confidence in their oncology breakthroug... |
| 15.07.2025 | Oncomatryx Biopharma Receives €12.5M EIC Accelerator Funding | Oncomatryx Biopharma, a Bilbao, Spain-based biotechnology company developing antibody-drug conjugates (ADCs) for oncology, received a €12.5M EIC Accelerator funding. The amount consisted of €2.5M in grant funding, along with a €10M equity i... |
| 15.07.2025 | Oncomatryx Biopharma Awarded €12.5 Million EIC Accelerator Funding to Advance Groundbreaking ADCs | BILBAO, Spain–(BUSINESS WIRE)–July 15, 2025– Oncomatryx Biopharma, a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology, has been awarded funding from the European Innovation Council (EIC) Accelera... |
| 29.01.2025 | Oncomatryx Secures €25 Million to Propel Cancer Research Forward | In the world of biopharmaceuticals, funding is the lifeblood that fuels innovation. On January 27, 2025, Oncomatryx, a biopharmaceutical company based in Zamudio, Spain, announced a significant milestone: the successful raising of €25 milli... |
| 27.01.2025 | Oncomatryx Raises €25M in Funding | Oncomatryx, a Zamudio, Spain-based biopharmaceutical company developing novel ADCs against the tumor microenvironment, raised €25M in funding. The round was led by existing investors and included a €10M strategic investment from Centro para... |
| 27.01.2025 | ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials | ZAMUDIO, Spain–(BUSINESS WIRE)–January 27, 2025– ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-... |
| 19.05.2023 | Oncomatryx Acquires Tube Pharmaceuticals | Oncomatryx, a Zamudio, Spain-based global bio-pharmaceutical company, acquired Tube Pharmaceuticals GmbH, the Austrian developer of the Cytolysintoxic payload. The amount of the deal was not disclosed. The multimillion euro transaction is a... |
| 18.05.2023 | Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment | ZAMUDIO, Spain–(BUSINESS WIRE)–May 18, 2023– Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload. The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its lead... |
| 31.05.2022 | Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors | BILBAO, Spain–(BUSINESS WIRE)–May 31, 2022– After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) ap... |
Show more